Acesion Pharma ApS is a Danish biotech company founded in 2011 and based in Copenhagen. Our technology is based on research initiated in 2008 at University of Copenhagen and chemistry insights from the company Neurosearch. Acesion Pharma aims to develop more efficacious and safe drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia.
Existing drug therapies generally have a limited effect or are associated with risk of serious adverse events, and there is a considerable patient need for developing better and safer drugs. Inhibition of SK channels, an ion channel relevant for regulating the heart rhythm, is a new and promising principle for the treatment of AF.